Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1626
Peer-review started: April 26, 2023
First decision: June 7, 2023
Revised: June 17, 2023
Accepted: July 29, 2023
Article in press: July 29, 2023
Published online: September 15, 2023
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, derived from a composite evaluation of markers reflecting the tumor-inflammation relationship and nutritional status, has been substantiated as a noteworthy prognostic determinant for diverse malignancies. A scoring system incorporating clinical and laboratory data may hold utility in determining the prognosis of gastric cancer.
The need for healthcare professionals to utilize supportive tools in predicting prognosis and making treatment decisions in metastatic gastric cancer.
To investigate how the HALP score relates to prognosis in patients with metastatic gastric cancer.
This retrospective study cohort comprised 147 patients with metastatic gastric cancer. The cutoff values for the HALP score, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio were determined using receiver operating characteristic analysis. Low HALP scores were defined as those less than 24.79 and high HALP scores as those greater than 24.79.
The median overall survival was significantly superior in patients with high HALP score than those with low HALP score (10.4 mo vs 7.5 mo, respectively; P < 0.001).
The HALP score was found to be a prognostic factor in patients with metastatic gastric cancer.
Given its simplicity and low cost, we think the HALP score can be utilized to manage patients with gastric cancer.